However, the concomitant activation of Wnt/β-catenin signaling and expression of a constitutively active KRAS mutant, such as KRASG12D, led to a marked increase of tumor formation, in terms of both tumor size and number of tumor lesions, compared with KRASG12D alone. This evidence concerns the gene KRAS and neoplasm.